Biocon’s arm expands insulin access in Malaysia

30 Jun 2025 Evaluate

Biocon’s subsidiary -- Biocon Biologics has surpassed the milestone of supplying 100 million cartridges of recombinant human insulin (rh-insulin) to Malaysia’s Ministry of Health (MoH). This achievement reinforces Biocon Biologics’ long-standing commitment to advancing diabetes care and ensuring affordable access to insulin across the country.

Since entering the Malaysian market in 2016, Biocon Biologics has played a pivotal role in transforming diabetes management, and has supplied over 100 million cartridges of rh-insulin serving over 345,000 patients. Biocon Biologics’ public-private partnership with the Malaysian government exemplifies a successful model for building a resilient biotech ecosystem by driving innovation, developing local talent, enabling better patient outcomes and advancing insulin self-sufficiency in Malaysia.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

392.55 4.30 (1.11%)
05-Dec-2025 15:04 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.15
Dr. Reddys Lab 1275.50
Cipla 1521.80
Zydus Lifesciences 931.80
Lupin 2100.85
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×